TripleBlind Announces Partnership with SEQSTER to Accelerate Data-Driven Patient Outcomes
Pharmaceutical companies and healthcare organizations will now have access to plug-and-play compatibility for clinical trials and beyond
TripleBlind, the leader in privacy-enhancing computation (PEC), announced a technology and go-to-market partnership with SEQSTER PDM Inc. (“SEQSTER”), the leader in patient-centric healthcare data technology, to develop a privacy preserving end-to-end data solution. This new partnership will enable healthcare organizations and pharmaceutical companies to gain important insights from data and improve patient outcomes.
“SEQSTER has solved one of the biggest problems in healthcare: patient real-time access to health data, so why shouldn’t we do the same for healthcare organizations?” said Riddhiman Das, Co-founder and CEO of TripleBlind. “Together, TripleBlind and SEQSTER are now able to provide researchers and data scientists with access to incredibly valuable data that will spur innovation in the healthcare industry and, ultimately, save lives.”
Historically, healthcare data has been siloed and things like clinical trials have required manual data entry. As the healthcare industry continues to move towards digital transformation, health organizations increasingly need the ability to aggregate multiple, disparate data sources in real time to gain actionable insights for research and development. TripleBlind and SEQSTER’s privacy preserving end-to-end data platform reduces the costs associated with digital evolution in the healthcare industry, while more effectively and efficiently protecting the privacy of data.
Marketing Technology News: MarTech Interview with Greg Goldfarb, VP Commerce Products at GoDaddy
“We’ve tackled the biggest issues in healthcare – data accessibility and data interoperability – yet there’s still a major opportunity to more efficiently use data from clinical trials to improve patient reported outcomes. To say that I’m excited about our new partnership with TripleBlind is an understatement – the combination of these two technologies will be impactful for researchers, patients, and Pharma enterprises at scale.”
Marketing Technology News: Building A Career in Enterprise Marketing
